Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2019 Jan 10;14(1):e0210422. doi: 10.1371/journal.pone.0210422

Prevalence and determinants of anti-tuberculosis treatment non-adherence in Ethiopia: A systematic review and meta-analysis

Abriham Zegeye 1,*, Getnet Dessie 2, Fasil Wagnew 3, Alemu Gebrie 1, Sheikh Mohammed Shariful Islam 4,5, Bekele Tesfaye 3, Dessalegn Kiross 6
Editor: Anna Maria Mandalakas7
PMCID: PMC6328265  PMID: 30629684

Abstract

Background

Tuberculosis is a global public health problem. One of the overarching dilemmas and challenges facing most tuberculosis program is non-adherence to treatment. However, in Ethiopia there are few studies with variable and inconsistent findings regarding non-adherence to treatment for tuberculosis.

Methods

This systematic review and meta-analysis was conducted to determine the prevalence of non-adherence to tuberculosis treatment and its determinants in Ethiopia. Biomedical databases including PubMed, Google Scholar, Science Direct, HINARI, EMBASE and Cochrane Library were systematically and comprehensively searched. To estimate the pooled prevalence, studies reporting the prevalence of adherence or non-adherence to tuberculosis treatment and its determinants were included. Data were extracted using a standardized data extraction tool prepared in Microsoft Excel and transferred to STATA/se version-14 statistical software for further analyses. To assess heterogeneity, the Cochrane Q test statistics and I2 test were performed. Since the included studies exhibited high heterogeneity, a random effects model meta- analysis was used to estimate the pooled prevalence of non-adherence to tuberculosis treatment. Finally, the association between determinant factors and non-adherence to tuberculosis treatment was assessed.

Results

The result of 13 studies revealed that the pooled prevalence of non-adherence to tuberculosis treatment in Ethiopia was found to be 21.29% (95% CI: 15.75, 26.68). In the subgroup analysis, the highest prevalence was observed in Southern Nations and Nationalities of Ethiopia, 23.61% (95% CI: 21.05, 26.17) whereas the lowest prevalence was observed in Amhara region, 10.0% (95% CI: 6.48, 13.17.0;). Forgetfulness (OR = 3.22, 95% CI = 2.28, 4.53), fear side effect of the drugs (OR = 1.93, 95% CI = 1.37, 2.74), waiting time ≥ 1 hour during service (OR = 4.88, 95% CI = 3.44, 6.91) and feeling distance to health institution is long (OR = 5.35, 95% CI = 4.00, 7.16) were found to be determinants of non-adherence to tuberculosis treatment.

Conclusion

In this meta-analysis, the pooled prevalence of non-adherence to tuberculosis treatment in Ethiopia was high. Forgetfulness, fear of side effect of the drugs, long waiting time (≥1 hour) during service and feeling distance to health institution is long were the main risk factors for non-adherence to tuberculosis treatment in Ethiopia. Early monitoring of the side effects and other reasons which account for missing medication may increase medication adherence in patients with tuberculosis in Ethiopia.

Background

Tuberculosis (TB) is a communicable disease caused by the bacillus Mycobacterium tuberculosis. It usually affects the lungs (pulmonary TB) and transmitted when people who are sick with pulmonary TB expel bacteria into the air, but can also affect other sites (extra pulmonary TB) [1].

TB is a global public health problem; approximately one third of the world population is infected by Tubercle bacilli and at risk of developing active disease [2]. In 2016, globally there were an estimated 10·4 million new cases of tuberculosis, and 600 000 new cases with resistance to Rifampicin (the most powerful first-line drug) [3]. Ninety percent of total TB cases and deaths occur in the developing world. Among those, 75% of cases are in the most economically productive age group [4].

According to the World Health Organization (WHO) TB control report, among the world’s 22 high-burden TB countries, Ethiopia ranks seventh [5]. Agreeing to the ministry of health, TB is the second cause of death after malaria, the third cause of hospital admissions and a main reason of morbidity in Ethiopia. The expected TB incidence in Ethiopia was 261/100,000 inhabitants in 2011. In Ethiopia, almost 50–60% of people living with HIV and 10% HIV-negative people have life-time risk of developing TB [6, 7].

Worldwide, the implementation of Directly Observed Treatment (DOT) has been related to decreased rate of treatment failure, relapse and drug resistance. However, its influence on decreasing TB incidence has been inadequate by non-compliance to DOT, which happens when patients do not turn up for treatment at health facility or community DOT points [8]. According to the WHO’s report on worldwide plan to halt TB, poor treatment has been caused by evolution of Mycobacterium tuberculosis strains that do not respond to treatment with standard first line combination of anti-TB medicines, resulting in the emergence of multi drug resistance TB (MDR-TB) in almost every country of the world [5]. One of the overarching dilemmas and challenges facing most TB program’s is a patient that does not complete TB treatment for one reason or another [9].

There is an unfavorable magnitude of poor adherence to treatment of chronic diseases including TB in the world [10]. However, greater than 90% of patients with TB are expected to adhere the treatment in order to facilitate cure. Poor adherence to treatment results failure of cure which increases the risk of development of drug resistant strains, spread of TB in the community and this in turn increases morbidity and mortality [11, 12].

Although many national and international efforts have been implemented against TB prevention and control, still patients are failing to complete their treatment to declare cure even with execution of globally recommended strategy (DOT) in almost all parts of the WHO regions [13–15]. According to the current WHO report, throughout the world, significant TB patients have not recovered after several treatments. Some of obstacles are defaulting from treatment, relapsing after completion of the treatment and developing MDR-TB among retreatment cases [16].

In developing countries, particularly, there are many factors affecting adherence to TB treatment as evidenced from a variety of literatures. Age, lack of treatment support from family, extreme illness, far distance, lack of access to formal health services, traditional beliefs leading to self-treatment, low income, lack of social support, drug side effects, pill burden, lack of food, stigma with lack of disclosure, and lack of adequate communication with health professionals were some of the documented factors [5, 17–21].

In Ethiopia, different studies have been conducted to determine the prevalence and determinants of non-adherence to TB medications [22–34]. Those studies reported that the prevalence of non-adherence among TB patients ranging from 8.4% to 55.8%. This is higher than the WHO recommendation of less than 10% [35]. Variable and inconsistent prevalence and determinants of non-adherence were observed in the reported studies. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence of non-adherence to TB treatment and its determinants in Ethiopia. A better understanding of the magnitude and reasons for non-adherence to TB treatment will help in planning and implementing future strategies for the control of the disease.

Methods

Data sources and search strategy

Studies reporting the prevalence of non-adherence to TB treatment in Ethiopia were systematically and comprehensively searched using biomedical databases; PubMed, Google Scholar, Science Direct, HINARI, EMBASE and Cochrane Library according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline [36].

All published and unpublished original articles with epidemiological data on the prevalence and associated factors of adherence or non-adherence to TB treatment conducted in Ethiopia from 1980 to February 2018 were included in this review. Manual searches for additional relevant studies using references from retrieved articles were also performed. Studies were searched by using the following keywords separately or in combination: “Tuberculosis”, “Adherence to TB medication”, “Non-adherence to TB medication”, “Ethiopia”, “Prevalence” and “Associated factors”. The search terms were used separately and in combination using Boolean operators like “OR” or “AND” (S1 File).

Inclusion criteria

Studies which fulfilled the following criteria were included after systematically reviewing the content of the manuscripts.

  • Publication type: journal articles, master’s thesis and dissertations

  • Setting: community or institutional based studies in different regions of Ethiopia

  • Participants: people of all ages, regardless of their sex and occupation.

  • Language: articles published in English language.

  • Study design: studies that assessed the prevalence and associated factors of non-adherence to TB medications.

  • Study area and period: only studies conducted in Ethiopia from 1980 to February 2018 were included in the review.

Exclusion criteria

  • Conference abstracts

  • Articles which assessed non-adherence to TB treatment among people living with HIV only

  • Articles with incomplete information, methodological problems or no full text available were also excluded, because this may limit the analyses.

Data extraction and quality assessment

The data extraction was done by two investigators independently using Microsoft Excel with a tool. This tool included information on the author, year of publication, region, study design, sample size, included participants, and number of patients with non-adherence treatment, TB prevalence rates and risk factors significantly related to non-adherence in TB patients.

Among the articles identified, titles and abstracts were reviewed to retrieve studies on the prevalence of non-adherence to TB treatment. Articles found relevant by title and abstract screened for full text review for eligibility. The quality of eligible studies was assessed against predefined inclusion criteria and the quality assessment tool for cross sectional studies known as Newcastle-Ottawa Scale [37]. High quality articles were determined if scale score was 6 and above out of 10. Two investigators conducted the selection, extraction and quality assessment of articles independently. Inconsistencies between the investigators were solved by discussion and articles were included after consensus.

Outcome measurement

Anti-TB treatment adherence status was the outcome variable dichotomized as adherent and non-adherent. A patient belonging to either intensive or continuation phase under new or retreatment regimen who missed ≥10% of the total prescribed dose was considered as non-adherent. For sputum follow up, patients who missed one and more sputum tests were considered as non-adherent. The primary outcome of this study was the prevalence of non-adherence to TB treatment. The prevalence was calculated by dividing the number of TB patients who did not adhere by the total number of study subjects multiplied by 100. The second outcome considered in this systematic review and meta-analysis was a risk factor that is associated with non-adherence to TB treatment. For the analysis of the risk factors, we considered and collected risk factors which were mentioned in two or more studies by looking at the two by two tables of the factors reported in each study. E-mails were sent to the corresponding or first authors of the studies or abstracts for missing information and a waiting time of 3–4 weeks were taken for the responses. If there were no responses, we excluded the study or the parameter that was not available.

Statistical methods, publication bias, heterogeneity and analysis

The necessary information from each original study was extracted by using a format prepared in Microsoft Excel spreadsheet. Then, the data were transferred into STATA/se version-14 statistical software for further analyses. For studies which did not present it, a standard error (SE), was calculated using the formula: SE = √p x (1-p)/n in Microsoft excel. The calculated standard error and prevalence rate of each study was then entered into STATA/se version-14 software to calculate the overall prevalence and its 95% CI.

Publication bias and heterogeneity were also assessed. To check publication bias, a funnel plot, Egger’s and Begg’s tests at 5% significant level were performed. The distribution of studies and a p-value <0.05 were used to declare publication bias. The heterogeneity of studies was checked using Cochran’s Q test (P < 0.10 indicated statistically significant heterogeneity) and I2 test statistics (which shows the amount of heterogeneity between studies). A naive categorization of values for I2 would not be appropriate for all circumstances, although we would tentatively assign adjectives of low, moderate, and high to I2 values of 25%, 50%, and 75% respectively [37]. The test result indicated the presence of significant heterogeneity; as a result, a random effects model was used to estimate the Der Simonian and Laird's pooled effect.

The pooled effect size was computed in the form of prevalence and odds ratio. To minimize the random variations between the point estimates of the primary study, subgroup analysis was carried out based on the geographical settings (regions). In addition, to identify the possible source of heterogeneity, univariate meta regression was performed by considering the sample size of each study. Furthermore, point prevalence with 95% CIs were presented in forest plot. In this plot, the size of each box indicates the weight of the study, while each crossed line refers to 95% CI. To identify possible determinants, pooled effect was articulated in the form of odds ratio. Sensitivity analysis was also performed to identify the primary determinant of the pooled result and the main source of heterogeneity.

Results

Literature searches and selection

We identified 354 articles in the electronic search databases of MEDLINE/PubMed, Google Scholar, Science Direct, HINARI, EMBASE, Cochrane Library and reference lists of previous relevant studies to identify more related literatures in the initial screening. From these, 126 records remained after removing duplication. After assessing and screening the titles and abstracts, 53 records were excluded. We assessed the full texts of 32 remaining records for eligibility, and 19 records were further excluded for not fulfilling the inclusion criteria. Finally, 13 of the retrieved studies were included in the meta-analyses [22–34] (Fig 1).

Fig 1. Flow chart diagram describing selection of studies for the systematic review and meta-analysis of prevalence and determinants of non-adherence to anti TB medication in Ethiopia, 2018.

Fig 1

Open in a new tab

Characteristics of the original articles

Table 1 summarizes the characteristics of 13 original articles included in this systematic review and meta-analysis. Twelve of 13 articles were cross sectional studies and one was prospective cohort study design conducted in Ethiopian TB patients [38]. Sample size ranged from 24 in Tercha District Hospital in South Ethiopia [26] to 404 in Hosanna Zonal Hospital in Hadiya zone of the southern region of Ethiopia [38]. All studies were carried out between 2007 and 2017. A total of 2797 Ethiopian TB patients were included to estimate the pooled prevalence of non-adherence to anti TB medication in the present meta-analysis. The studies were conducted in different regions of the country: Amhara [28], Tigray [22, 29, 30, 32], Oromia [24, 33, 34] and Southern Nations and Nationalities of Ethiopia [23, 25–27, 31].

Table 1. Summary of included studies evaluating the prevalence and risk factors of non-adherence to anti TB medication in Ethiopia.

Author, Year Study design Region Sample size Response rate (%) Prevalence (95% CI) Quality score
Nezenga ZS et al, 2013 Cross-sectional SNNP
 531
 95.5
 26.00 (22.18, 29.82) 5
Woimo TT et al, 2017 Cross-sectional SNNP 271 96.3 24.50 (19.28, 29.72) 7
Adane AA et al, 2013 Cross-sectional Amhara 280 99.6 10.00 (6.48, 13.52) 6
Kebede A et al, 2012 Cross-sectional SNNP 24 100 20.80 (4.56, 37.04 7
Getachew et al, 2015 Cross-sectional Tigray 162 95 18.00 (11.93, 24.07 5
Yusuf KO et al, 2015 Cross-sectional Oromia 126 72.2 29.67 (20.28, 39.06) 7
Daksa et al, 2016 Cross-sectional Oromia 67 100 12.00 (4.22, 19.78) 7
Tesfahuneygn et al, 2015 Cross-sectional Tigray 200 100 11.50 (7.08, 15.92) 7
Gubie AA et al, 2017 Cross-sectional SNNP 281 96.4 24.70 (19.57, 29.83 5
Shargie EB et al, 2007 Cohort SNNP 404 97.8 20.00 (16.04, 23.96) 6
Eticha T et al, 2014 Cross-sectional Tigray 120 100 55.80 (46.91, 64.69) 7
Ahmed Yasin et al, 2014 Cross-sectional Oromia 53 100 20.70 (9.79, 31.61) 7
Kiros YK et al, 2014 Cross-sectional Tigray 278 98 8.40 (5.10, 11.70 5
Open in a new tab

Abbreviations: SNNP Southern Nations Nationalities and Peoples, TB Tuberculosis, CI Confidence Interval

Meta-analysis

Thirteen studies were included for the analysis to determine the prevalence of non-adherence to anti TB medication. The overall pooled prevalence was found to be 21.29% (15.75, 26.83) (Fig 2). The test statistic showed a high heterogeneity among the studies (I2 = 92.9%, p<0.001). As a result, random effects model was used to estimate the Der Simonian and Laird's pooled effect.

Fig 2. Forest plot depicting the pooled prevalence of non-adherence to anti TB medication in Ethiopia.

Fig 2

Open in a new tab

We assessed publication bias by looking at the funnel plot for symmetry by visual inspection (Fig 3). The funnel plot appeared quite symmetrical and showed no publication bias. The Egger weighted regression (p = 0.103) and Begg rank correlation test (p = 0.428) also revealed evidence of no publication bias.

Fig 3. Funnel plot to assess publication bias for non-adherence to anti TB treatment in Ethiopia.

Fig 3

Open in a new tab

In addition, in this meta-analysis, we preformed subgroup analyses based on the geographical setting (region of the country) of the studies. The pooled prevalence estimate of non-adherence to anti TB treatment was highest in the Southern Nations and Nationalities of Ethiopia, 23.61% (95% CI: 21.05, 26.17), followed by Tigray region with a prevalence of 22.87% (95%CI: 8.27, 37.46) and the least was in Amhara region, 10.0% (95% CI: 6.48, 13.17.0) (Fig 4).

Fig 4. Forest plot depicting subgroup analysis of non-adherence to anti TB medication in Ethiopia according to the location of the studies assessed.

Fig 4

Open in a new tab

Risk factor analysis

The risk/associated factors for tuberculosis non-adherence were heterogeneous. Eight of studies included a discussion of risk factors associated with non-adherence. The remaining five studies did not incorporate risk factor analysis. These risk factors frequently discussed in the majority of the studies were employment status, educational status, relationship with health workers, proper counseling, means of transportation, forgetfulness, fear of side effect of the drug, long waiting time in health institutions and feeling distance to health institution is long. A number of studies concluded that non-formal education increases the risk of non-adherence to TB treatment [25, 27, 33, 34]. Poor knowledge and poor counseling services were also reported as factors associated with non-adherence to TB treatment [22, 25, 33]. On the contrary, good relationship with care providers was reported as a low risk factor for non-adherence to TB [23, 25, 33, 34]. Being farmer and transportation on foot to health institutions were reported as increased risk factors for non-adherence to anti TB treatment [23, 25, 30]. We were able to perform a meta-analysis on four of the risk factors. The pooled odds ratios ranged from 1.93 (fear of side effect of the drug) to 5.35 (distance to health institution).

Forgetfulness and non-adherence of anti TB treatment

This review assessed the association between forgetfulness of the patients with non-adherence to anti TB medication. The pooled regression analysis of four studies [22, 23, 27, 28] showed a higher risk of non-adherence to TB medication among those who forget to take their medication, OR = 3.22 (95% CI = 2.28, 4.53). The studies included in this analysis were heterogeneous as evidenced by I2 (I2 = 95.8%, p<0.001) and non-significant publication bias (p-value = 0.790) (Fig 5A).

Fig 5.

Fig 5

Open in a new tab

Forest plot depicting pooled odds ratio (log scale) of the associations between non-adherence to Anti TB medication and its purported determinants (A: forgetfulness B: fear of side effect of drugs C: long waiting time in health institution D: feeling distance to health institution is long).

Fear of side effect of the drug and non-adherence of anti TB medication

In this subcategory analysis, five articles were included [23, 25, 28–30]. Those studies showed a statistically significant association of fear of side effect of drug with non-adherence of anti TB medication, having higher risk of non-adherence among those who fear side effect of the drugs OR = 1.93 (95% CI = 1.37, 2.74). The studies included in this analysis were heterogeneous as evidenced by I2 (I2 = 92.9%, p<0.001) and there was no publication bias as indicated by the Egger’s regression test (p-value = 0.076). Therefore, a random effects model was used to estimate the effect of fear of side effect of the drug and non-adherence of anti TB medication (Fig 5B).

Association between long waiting time (≥1 hour) in health institutions and non-adherence to anti TB treatment

Four studies were included in this category of meta-analysis [22, 23, 25, 30]. The final pooled Meta regression analysis showed statistically significant difference between long waiting time (≥1 hour) in health institutions and non-adherence to anti TB treatment, OR = 4.88 (95% CI = 3.44, 6.91). High heterogeneity was observed in this category of meta-analysis, I2 = 92.1%, p<0.001. However, the test for publication bias using the Egger’s test showed non-statistical significant publication bias, p-value = 0.223 (Fig 5C).

Association between feeling distance to health institution is long and non-adherence to anti TB treatment

In this subcategory analysis, six articles were included [22, 23, 27, 30, 33]. The pooled meta regression analysis showed that there was statistically significant difference in the occurrence of non-adherence to anti TB treatment among those who feel distance to health institution is long, OR = 5.35 (95% CI = 4.00, 7.16)). The studies included in this analysis were heterogeneous as evidenced by (I2 = 89.9%, p<0.001) and there was no publication bias as indicated by the Egger’s regression test (p-value = 0.699). Therefore, a random effects model was used to estimate the association between feeling distance to health institution is long and non-adherence to Anti TB treatment (Fig 5D)

Discussion

Data containing 2797 Ethiopian TB patients were included in the present study. A total of 13 studies were included in the meta-analysis. The study assessed the prevalence of anti TB drug non-adherence and its determinants among TB patients attending Ethiopian health institutions.

Frequently used definition of non-adherence is a patient who had missed 10% or more of the total prescribed doses of TB drugs, even if it is recommended that every TB patient should adhere to anti-TB medication by following the DOTS strategy [1]. Non-adherence to anti-TB treatment might lead to an increased risk of drug resistance and a prolonged infectiousness, in addition to relapse and death. Thus, data obtained from this review is essential for planning, implementing and evaluating advocacy, communication and social mobilization work [39].

The finding from this study showed that 21.29% of TB patients did not adhere to anti TB drugs. Regional variation in non-adherence to anti TB medication was observed, the highest prevalence of non-adherence (18.25%) was reported in Southern Nations and Nationalities of Ethiopia, 23.61% followed by Tigray region with a prevalence of 22.87% and the least was in Amhara studies 10.0%. This can be plausibly explained by the fact that though life in Amhara farming society is hard, many Amhara’s took medication appropriately since they do not want to look ill in front of their families and friends for their better survival. Moreover, resource-limited settings present unique challenges to Anti TB medication adherence. A multitude of structural barriers prevent access to health care and the regular supply of anti-TB drugs. These include the cost of medical care, drugs, and the difficulty of making follow-up appointments due to long distances, family responsibilities and the prohibitive cost of transportation across regions.

This finding is lower compared to the finding from studies conducted in Tertiary health institution in South East Nigeria, in Sub-Saharan Africa and in South Ethiopia where non-adherence to anti TB drug was reported to be 24.2%, 40% and 24.5% respectively [24, 25, 40]. However, these rates are higher than the WHO recommendation of less than 10% [35]. This dissimilarity might be due to socio-cultural differences, variability in TB patient risk factor distribution, and the difference in health service accessibility.

Random effects model was used in our systematic review and meta-analysis, bearing in mind the chances of substantial heterogeneity between studies which were confirmed with the Q test. The pooled prevalence of subgroup analysis revealed clear differences on the prevalence of non-adherence among the regions: Southern Nations and Nationalities of Ethiopia studies reported high prevalence of non-adherence to anti TB treatment followed by Tigray region studies. This discrepancy might be due to the methodological, socio demographic and economic differences between the regions.

It is important to remind that participants were evaluated through self-reported records that measured non-adherence to TB treatment, rather than gold-standard diagnostic clinical interviews in inferring the results of this systematic review and meta-analysis. In addition, even if each self-report measures of non-adherence to TB treatment have limitations, there is indication that among TB patients the lack of anonymity in formal screening assessments may compromise precise assessment of sensitive personal information. Resource-limited settings present unique challenges to anti-TB adherence [18, 19, 21, 33, 41].

Different physical barriers prevent access to health care and the regular supply of anti TB drugs.

Our study have shown that among the Ethiopian TB patients, forgetfulness, fear of side effect of the drug, long waiting time in health institutions and feeling distance to health institution is long were the most significant factors predicting non-adherence which is consistent with earlier studies [42–45].

Our systematic review identified various risk factors associated with non-adherence to anti TB treatment. Most of the factors associated with treatment non-adherence are those related to physical access to health-care services: distance from home to treatment center, employment status, rural residence and a need to use public transport for ambulatory care. In other settings, risk factors such as knowledge about anti TB treatment duration, educational status, poor patient–health provider communication, and medication side effects were reported to have been associated with anti TB treatment non-adherence. This is may be due to less understanding about the disease relapse, resistance and treatment failure in less educated patients. Currently, in Ethiopia, TB treatment is being provided freely at the community, grass root level. However, some patients still questioned the accessibility of TB related services.

Similarly, study conducted in India and Namibia reported that the non-adherence to TB treatment was significantly higher among those who were less educated, unskilled worker, low family income and lower-class family. This may be due to less understanding about the disease relapse, resistance and treatment failure in less educated patients [8, 46]. In this study, forgetfulness showed a significant association with non-adherence to TB treatment. An increment in the overall patient forgetfulness has a positive effect on patient non-adherence to TB treatment. This is consistent with the previous studies in different regions of Ethiopia [26, 41, 47]. This problem may be related to older age which is related with encephalopathy or dementia. From this study long waiting time in health institutions and feeling distance to health institution is long were the main reasons for non-adherence as in line with study done in Peru and Russia in which distance was the main reason for non-adherence followed by feeling better and lack of family support [48, 49]. TB treatment is provided as per DOT principle in Ethiopia, which is difficult for patients to collect their medication every day from the clinics [7]. This suggests that distance from the clinic might be the main barrier for adherence in TB patients. as reported from a study in Southern Ethiopia, side effects of the drugs is also an important reason for anti TB drug non-adherence among TB patients [25]. Whilst the likelihood of not adhering to anti TB drugs among TB patients with side effects of the drugs is almost twice to those without the side effects. This finding is in line with previous reports of studies carried out in Tigray, Northern Ethiopia, where side effects of TB drugs was one of the main reasons for non-adherence among TB patients [30, 32].

Limitations of the study

The main limitation of this study was that the data were derived from studies that used different screening methods, the prevalence of non-adherence to anti TB medication could not be precisely determined. Second, all of the studies included in this review were cross-sectional in design; it neither represents seasonal variation of non-adherence outcomes nor establishes causal relationship. In addition, only articles published in English language were considered to include in this review. It should also be noted that some of the studies included in this review had a small sample size which could affect the estimated report.

Conclusion

In this meta-analysis, studies revealed that the prevalence of non-adherence to anti-TB drugs among TB patients in Ethiopia was relatively high. Forgetfulness, fear of side effect of the drug, long waiting time in health institutions and feeling distance to health institution is long were significant determinants of non-adherence to anti-TB drugs. Therefore, based on our findings, we recommend that policies should be developed to strengthen the treatment management of TB patients. Where possible, decentralization of DOTs service to lower level of health facility structure should be prioritized.Moreover, side effects and other reasons which account for missing medication should be monitored early so that patients will adhere more to their medications.

Supporting information

S1 File. supplementary file search strategy.

(DOCX)

Click here for additional data file. (17.5KB, docx)

Acknowledgments

We would like to express our gratitude and appreciation to all staffs of Debre Markos University of Medicine and Health Sciences who assisted us in this review.

Abbreviations

DOT

Directly Observed Treatment

TB

Tuberculosis

HIV

Human Immunodeficiency Virus

MDR-TB

Multi Drug Resistance–Tuberculosis

WHO

World Health Organization

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Organization WH. Global tuberculosis report 2016. 2016.
  • 2.Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. Jama. 1999;282(7):677–86. [DOI] [PubMed] [Google Scholar]
  • 3.Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. The Lancet Respiratory Medicine. 2018;6(4):299–314. 10.1016/S2213-2600(18)30057-2 [DOI] [PubMed] [Google Scholar]
  • 4.Ahlburg DA, Initiative ST. The economic impacts of tuberculosis. 2000. [Google Scholar]
  • 5.Organization WH. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009: World Health Organization; 2009.
  • 6.Organization WH. Global tuberculosis report 2013: World Health Organization; 2013.
  • 7.FMoH E. Tuberculosis, Leprosy and TB/HIV Prevention and Control Programme. Addis Ababa, Ethiopia: 2008;207. [Google Scholar]
  • 8.Chani K. Factors affecting compliance to tuberculosis treatment in Andara Kavango region Namibia 2010.
  • 9.Rieder HL. Interventions for tuberculosis control and elimination: International Union Against Tuberculosis and Lung Disease Paris; 2002. [Google Scholar]
  • 10.Sabaté E. Adherence to long-term therapies: evidence for action: World Health Organization; 2003. [PubMed] [Google Scholar]
  • 11.Harries AD, Maher D, Graham S. TB/HIV: a clinical manual: World Health Organization; 2004. [Google Scholar]
  • 12.Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bulletin of the World Health Organization. 2008;86:B-D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Organization WH. WHO report 2008: global tuberculosis control: surveillance, planning, financing. WHO report 2008: global tuberculosis control: surveillance, planning, financing2008.
  • 14.Obermeyer Z, Abbott-Klafter J, Murray CJ. Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS One. 2008;3(3):e1721 10.1371/journal.pone.0001721 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yin X, Tu X, Tong Y, Yang R, Wang Y, Cao S, et al. Development and validation of a tuberculosis medication adherence scale. PLoS One. 2012;7(12):e50328 10.1371/journal.pone.0050328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Habteyes Hailu T, Azar T, Davoud SHOJAEIZADEH GG. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. Iranian journal of public health. 2015;44(1):1 [PMC free article] [PubMed] [Google Scholar]
  • 17.Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis-II. British medical journal (Clinical research ed). 1983;287(6385):101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC public health. 2010;10(1):651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gele AA, Sagbakken M, Abebe F, Bjune GA. Barriers to tuberculosis care: a qualitative study among Somali pastoralists in Ethiopia. BMC research notes. 2010;3(1):86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sagbakken M, Frich JC, Bjune G. Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study. BMC public health. 2008;8(1):11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bagchi S, Ambe G, Sathiakumar N. Determinants of poor adherence to anti-tuberculosis treatment in Mumbai, India. International journal of preventive medicine. 2010;1(4):223 [PMC free article] [PubMed] [Google Scholar]
  • 22.Tesfahuneygn G, Medhin G, Legesse M. Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC research notes. 2015;8(1):503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.GUBE AA, DEBALKIE M, SEID K, BISETE K, MENGESHA A, ZEYNU A, et al. ASSESSMENT OF ANTI TB DRUG NON-ADHERENCE AND ITS ASSOCIATED FACTORS AMONG TB PATIENTS ATTENDING TB CLINICS IN ARBA MINCH GOVERNMENTAL HEALTH INSTITUTIONS, SOUTHERN ETHIOPIA. [DOI] [PMC free article] [PubMed]
  • 24.Yusuf KO, Seifu MF, Gelaw BK, Gebremariam ET. Non Adherence and its Contributing Factors to Anti-TB Drug in Children†s at Adama Referral Hospital, Oromia, Ethiopia. Global Journal of Medical Research. 2015. [Google Scholar]
  • 25.Woimo TT, Yimer WK, Bati T, Gesesew HA. The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia: a cross-sectional study. BMC public health. 2017;17(1):269 10.1186/s12889-017-4188-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kebede A, Wabe NT. Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in South West Ethiopia. North American journal of medical sciences. 2012;4(2):67 10.4103/1947-2714.93376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shargie EB, Lindtjørn B. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. PLoS medicine. 2007;4(2):e37 10.1371/journal.pmed.0040037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Adane AA, Alene KA, Koye DN, Zeleke BM. Non-adherence to anti-tuberculosis treatment and determinant factors among patients with tuberculosis in northwest Ethiopia. PloS one. 2013;8(11):e78791 10.1371/journal.pone.0078791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kiros Y, Teklu T, Desalegn F, Tesfay M, Klinkenberg E, Mulugeta A. Adherence to anti-tuberculosis treatment in Tigray, Northern Ethiopia. Public health action. 2014;4(3):S31–S6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Eticha T, Kassa E. Non-Adherence to Anti-TB Drugs and Its Predictors among TB/HIV Co-Infected Patients in Mekelle, Ethiopia. Journal of Bioanalysis and Biomedicine. 2014;6(6):61. [Google Scholar]
  • 31.Nezenega ZS, Tafere TE. Patient satisfaction on tuberculosis treatment service and adherence to treatment in public health facilities of Sidama zone, South Ethiopia. BMC health services research. 2013;13(1):110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.al. Ge. LEVEL OF PATIENT ADHERENCE TO ANTI-TUBERCULOSIS TREATMENT IN MEKELLE TUBERCULOSIS DIRECT OBSERVED THERAPY CENTERS, TIGRAY, NORTH ETHIOPIA. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. 2015;4(04):166–81. [Google Scholar]
  • 33.al De. Patients’ adherence to anti-tuberculosis medicines and associated factors for non-adherence at a tertiary teaching hospital, South West Ethiopia. Gaziantep Medical Journal 2016;22(2):55–62. [Google Scholar]
  • 34.al AYe. Treatment Adherence among Tuberculosis and Human Immuno Deficiency Virus Coinfected Patients in Ginnir Referral Hospital. American Journal of Public Health Research. 2014;2(6):239–43. [Google Scholar]
  • 35.Organization WH. World Health Organization global tuberculosis control report 2009. Global tuberculosis control. 2011.
  • 36.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine. 2009;6(7):e1000100 10.1371/journal.pmed.1000100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003;327(7414):557 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Shargie EB, Lindtjorn B. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. PLoS Med. 2007;4(2):e37 10.1371/journal.pmed.0040037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2(11):7.9–1.4. [DOI] [PubMed] [Google Scholar]
  • 40.Ubajaka CF, Azuike EC, Ugoji JO, Nwibo OE, Ejiofor OC, Modebe IA, et al. Adherence to Drug Medications amongst Tuberculosis Patients in a Tertiary Health Institution in South East Nigeria. International Journal of Clinical Medicine. 2015;6(06):399. [Google Scholar]
  • 41.Abula T, Worki A. Patient non-compliance with drug regiments for chronic diseases in northwest Ethiopia. Ethiopian Journal of Health Development. 2001;15(3):185–92. [Google Scholar]
  • 42.Michael K, Belachew T, Jira C. Tuberculosis defaulters from the" dots" regimen in Jimma zone, southwest Ethiopia. Ethiopian medical journal. 2004;42(4):247–53. [PubMed] [Google Scholar]
  • 43.Tekle B, Mariam D, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. The International Journal of Tuberculosis and Lung Disease. 2002;6(7):573–9. [PubMed] [Google Scholar]
  • 44.Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS medicine. 2007;4(7):e238 10.1371/journal.pmed.0040238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bulletin of the World Health Organization. 2007;85:407–9. 10.2471/06.038927 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Santha T, Garg R, Frieden T, Chandrasekaran V, Subramani R, Gopi P, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. The International Journal of Tuberculosis and Lung Disease. 2002;6(9):780–8. [PubMed] [Google Scholar]
  • 47.Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia. BMC public health. 2015;15:572 10.1186/s12889-015-1933-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Culqui DR, Grijalva CG, Cayla JA, Horna-Campos O, Ch KA. Factors associated with the non-completion of conventional anti-tuberculosis treatment in Peru. Archivos de Bronconeumología (English Edition). 2012;48(5):150–5. 10.1016/j.arbres.2011.12.008 [DOI] [PubMed] [Google Scholar]
  • 49.Gelmanova I, Keshavjee S, Golubchikova V, Berezina V, Strelis AK, Yanova GV, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bulletin of the World Health Organization. 2007;85(9):703–11. 10.2471/BLT.06.038331 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 File. supplementary file search strategy.

(DOCX)

Click here for additional data file. (17.5KB, docx)

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES